|
|
|
| Submit a single random sample from one stool specimen collected in FOBT Sample Collection Device. (stool specimen should coat the ridges of the probe in sample bottle) |
 |
|
|
|
| Effective January 1, 2005, the volume of whole blood necessary for the performance of Prothrombin Gene Mutation testing is reduced to a minimum of 0.5 mL of whole blood in an EDTA tube. Volumes less than 0.5 mL may lead to failed isolations due to the dilution of the blood with anticoagulants. |
|
|
|
|
| Thin Prep vials for UFISH testing are available from the Molecular Pathology laboratory. Indicate the desired number of vials on a courier supply request form. |
|
|
|
|
| Effective 1/1/05, clients may choose to use the DNA with Pap option to screen their patients who are 30 years and older. |
|
|
|
|
| Effective July 29, 2005, NorDx will begin testing HIV-1 RNA Viral Load specimens in-house using the Bayer branched DNA (bDNA) methodology. This test is validated for Group M Subtypes A-G. The dynamic range of the assay is 75-500,000 copies/mL. |
|
|
|
|
| Effective January 1, 2005, the volume of whole blood necessary for the performance of HHDNA testing is reduced to a minimum of 0.5 mL of whole blood in an EDTA tube. Volumes less than 0.5 mL may lead to failed isolations due to the dilution of the blood with anticoagulants. |
|
|
|
|
| Used as a prognostic factor in stage II, node-positive breast cancer patients. An aid to predict disease-free and overall survival of the above patients when treated with cyclophosphamide, doxorubicin and 5-fluorouracil. Breast cancer patients with a 2+ IHC Her-2/neu stain who are candidates for Herceptin treatment.
|
|
|
|
|
| Effective July 29, 2005, NorDx will begin testing HCV RNA Viral Load specimens in-house using the Bayer branched DNA (bDNA) methodology. The dynamic range of the assay is 615 to 7,690,000 IU/mL. |
|
|
|
|
| Effective January 1, 2005, the volume of whole blood necessary for the performance of Factor V Leiden testing is reduced to a minimum of 0.5 mL of whole blood in an EDTA tube. |
|
|
|
|
| Effective April 1, 2004, testing for Cystic Fibrosis Carrier Screening and Genotyping on blood samples will be performed at NorDx laboratory. Amniotic Fluid and Chorionic Villus testing will continue to be performed at Mayo Medical Laboratories (Test Code 9497). |
|
